Avantor, Inc. 8-K

What Happened

• Avantor, Inc. filed a Form 8-K on April 23, 2026 reporting executive changes in its Bioscience and Medtech Products segment. On April 17, 2026 the company told Benoit Gourdier, Executive Vice President, Bioscience and Medtech Products, he will move to a role supporting segment integration and is expected to depart the company no later than December 31, 2026.
• The company also announced (via a press release furnished as Exhibit 99) that Ludovic Brellier will join Avantor as Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer, effective May 1, 2026.

Key Details

• Filing date: Form 8-K filed April 23, 2026 (Regulation FD disclosure).
• Transition: Benoit Gourdier notified April 17, 2026; expected departure on or before December 31, 2026.
• New hire: Ludovic Brellier to begin May 1, 2026 as EVP, Bioscience and Medtech Products and Chief Transformation Officer.
• Press release: Furnished as Exhibit 99 to the 8-K (not “filed” for Section 18 purposes).

Why It Matters

• This is a leadership change in Avantor’s bioscience and medtech segment and an explicit move to prioritize segment integration and transformation. For investors, the key points are continuity (Gourdier remains through the transition) and the appointment of a Chief Transformation Officer, which signals management focus on integration and operational change.
• The 8-K does not disclose compensation details or immediate financial impacts; investors should watch for further updates on succession, integration plans, and any related operational or financial disclosures.